Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 37c, Offers Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.39 +0.03%
EPS Growth %: -30.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -30.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.68, $0.37 better than the analyst estimate of $0.31. Revenue for the quarter came in at $152.6 million versus the consensus estimate of $141.49 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2026 revenue of $615-645 million, versus the consensus of $615.6 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump on Iran: we're trying to work out a deal that's fair
- Americas Silver Corporation (USAS) 14K contracts of August 6 calls trade, share price down 8%
- Varonis Said To Weigh Sale After Takeover Interest - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
